Recent antimalarial drug discovery has been a race to produce new medicines that
overcome emerging drug resistance, whilst considering safety and improving dosing …

Reducing the burden of infectious diseases that affect people in the developing world
requires sustained collaborative drug discovery efforts. The quality of the chemical starting …

This review focuses on key components of respiratory and photosynthetic energy-
transduction systems: the cytochrome bc 1 and b 6 f (Cyt bc 1/b 6 f) membranous …

Malaria elimination has recently been reinstated as a global health priority but current
therapies seem to be insufficient for the task. Elimination efforts require new drug classes …

Malaria is one of the most significant causes of childhood mortality, but disease control
efforts are threatened by resistance of the Plasmodium parasite to current therapies …

Tumour hypoxia renders cancer cells resistant to cancer therapy, resulting in markedly
worse clinical outcomes. To find clinical candidate compounds that reduce hypoxia in …

New antimalarial drugs are urgently needed to control drug-resistant forms of the malaria
parasite Plasmodium falciparum. Mitochondrial electron transport is the target of both …

The Malaria Drug Accelerator (MalDA) is a consortium of 15 leading scientific laboratories.
The aim of MalDA is to improve and accelerate the early antimalarial drug discovery process …

Atovaquone, a substituted hydroxynaphthoquinone, is a potent antimalarial drug that acts by
inhibiting the parasite's mitochondrial cytochrome bc 1 complex (cyt bc 1). Mutations in cyt …

The discovery of nalidixic acid is one pinnacle in medicinal chemistry, which opened a new
area of research that has led to the discovery of several life-saving antimicrobial agents …